# US 2021/0171629 A1 · Tim-3 antagonists for the treatment and diagnosis of cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171629 A1
- Document ID: US20210171629A1
- Status: Published application
- Kind: A1
- Application number: 16/642,511
- Filed: 2018-08-28
- Published: 2021-06-10
- Earliest claimed: 2017-08-28
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Anke KLIPPEL; Laurence Celine MENARD
- Web page: https://patentgrep.com/patent/US20210171629A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- G01N 33/57525: of the liver or pancreas
- G01N 33/505: {involving T-cells}
- G01N 33/5752: of the lungs
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are methods for treating a subject afflicted with a cancer, comprising administering to the subject a TIM3 agonist (e.g., an anti-TIM3 antibody), alone or in conjunction with another immune checkpoint inhibitor (e.g., a PD-1 antagonist), wherein the subject is identified as having a high frequency of TIM3 positive cells (e.g., on the tumor infiltrating inflammatory cells) or soluble TIM3 in peripheral blood. Also provided are methods for assessing the efficacy of a treatment comprising a TIM3 antagonist in a subject afflicted with a cancer, comprising measuring the frequency of TIM3 (and optionally PD-1) positive cells in certain populations of cells and/or the soluble TIM3 in peripheral blood of the subject, wherein a high frequency of TIM3 (and optionally PD-1) positive cells and/or the subject's peripheral blood titer of soluble TIM3 is indicative of the response to the treatment.

## Claims

### Claim 1

An in vitro method for determining whether a subject having a cancer would respond to a treatment with a TIM-3 antagonist, comprising determining a serum titer of soluble TIM-3 in the subject, and if (i) the serum titer of soluble TIM-3 is higher than that in healthy control subjects, or (ii) the serum titer of soluble TIM-3 is at least 2100, 2200, 2300, 2400, or 2500 pg/ml (as determined, e.g., in a method described in the Examples), the subject is likely to respond to a treatment with a TIM-3 antagonist.

### Claim 2

An in vitro method for determining whether a subject having a cancer would respond to a treatment with a TIM-3 antagonist, comprising determining a percentage of CD8+ TILs that are TIM-3 positive, and if the percentage is higher than 10%, 20%, 30%, 40%, 50%, 60% or 70%, the subject is likely to respond to a treatment with a TIM-3 antagonist.

### Claim 3

An in vitro method for determining whether a subject having a cancer would respond to a treatment with a TIM-3 antagonist, comprising determining a percentage of naïve TILs, central memory (CM) TILs, effector memory (EM) TILs, and effector TILs that are TIM-3 positive, and if the percentage of EM TILs and/or effector TILs that are positive for TIM-3 is higher than the percentage of naïve TILs and/or CM TILs that are positive for TIM-3, the subject is likely to respond to a treatment with a TIM-3 antagonist.

### Claim 4

An in vitro method for determining whether a subject having a cancer would respond to a treatment with a TIM-3 antagonist, comprising determining a percentage of dendritic cells, macrophages, and Natural Killer (NK) cells that are TIM-3 positive in TILs of the subject, and if the percentage is higher than that in control subjects (e.g., corresponding cancer patients who do not respond to treatment with a TIM-3 antagonist), the subject is likely to respond to a treatment with a TIM-3 antagonist.

### Claim 5

An in vitro method for determining whether a subject having a cancer would respond to a treatment with a combination of a PD-1/PD-L1 axis antagonist and a TIM-3 antagonist, comprising determining a frequency of PD-1 positive tumor infiltrating lymphocytes (TILs) and a frequency of TIM-3 positive TILs in the subject, wherein a co-expression of PD-1 and TIM-3 on at least 5% of CD8+ TILs of the subject indicates that the subject is likely to respond to a treatment with a combination of a PD-1/PD-L1 axis antagonist and a TIM3 antagonist.

### Claim 6

A method of treating a cancer in a subject in need thereof, comprising:
(1) (a) determining a serum titer of soluble TIM-3 in the subject, and (b) administering a TIM-3 antagonist to the subject if (i) the serum titer of soluble TIM-3 is higher than that in healthy control subjects, or (ii) the serum titer of soluble TIM-3 is at least 2100, 2200, 2300, 2400, or 2500 pg/ml (as determined, e.g., in a method described in the Examples);
(2) (a) determining a percentage of CD8+ TILs that are TIM-3 positive in the subject, and (b) administering a TIM-3 antagonist to the subject if the percentage is higher than 10%, 20%, 30%, 40%, 50%, 60% or 70%;
(3) (a) determining a percentage of naïve, central memory (CM), effector memory (EM), and effector TILs that are TIM-3 positive, and (b) administering a TIM-3 antagonist to the subject if the percentage of EM TILs and/or effector TILs that are positive for TIM-3 is higher than the percentage of naïve TILs and/or CM TILs that are positive for TIM-3; or
(4) (a) determining a percentage of dendritic cells, macrophages, and Natural Killer (NK) cells that are TIM-3 positive in TILs of the subject, and (b) administering a TIM-3 antagonist to the subject if the percentage is higher than that in control subjects (e.g., corresponding cancer patients who do not respond to treatment with a TIM-3 antagonist).

### Claim 7

A method of treating a cancer in a subject in need thereof, comprising: (i) determining a frequency of PD-1 positive tumor infiltrating lymphocytes (TILs) and a frequency of TIM-3 positive TILs in the subject, and (ii) administering a PD-1/PD-L1 axis antagonist in combination with a TIM-3 antagonist if at least 5% of CD8+ TILs co-express PD-1 and TIM-3.

### Claim 8 (depends on 3)

The in vitro method of claim 3, wherein the TIM-3 antagonist is an anti-TIM3 antibody.

### Claim 9 (depends on 8)

The in vitro method of claim 8, wherein the anti-TIM3 antibody comprises (i) a heavy chain variable region comprising CDR1, CDR2, and CDR3, and (ii) a light chain variable region comprising CDR1, CDR2, and CDR3, wherein
(a) the heavy chain CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 23-27;
(b) the heavy chain CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-38;
(c) the heavy chain CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 39-49;
(d) the light chain CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 50 and 51;
(e) the light chain CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 52 and 53; and
(f) the light chain CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 54-57.

### Claim 10 (depends on 3)

The in vitro method of claim 3, wherein the TILs are CD4+ TILs.

### Claim 11 (depends on 3)

The in vitro method of claim 3, wherein the TILs are CD8+ TILs.

### Claim 12 (depends on 5)

The in vitro method of claim 5, wherein the PD-1/PD-L1 axis antagonist comprises an anti-PD-1 antibody or an anti-PD-L1 antibody.

### Claim 13 (depends on 12)

The in vitro method of claim 12, wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, MEDI0608, AMP-224, PDR001, BGB-A317, or any combination thereof.

### Claim 14 (depends on 12)

The in vitro method of claim 12, wherein the anti-PD-L1 antibody comprises BMS-936559, MPDL3280A, MEDI4736, MSB0010718C, or any combination thereof.

### Claim 15 (depends on 3)

The in vitro method of claim 3, wherein the cancer comprises a colon, kidney, or lung cancer.

### Claim 16 (depends on 7)

The method of claim 7, wherein the PD-1/PD-L1 axis antagonist comprises an anti-PD-1 antibody or an anti-PD-L1 antibody.

### Claim 17 (depends on 16)

The method of claim 16, wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, MEDI0608, AMP-224, PDR001, BGB-A317, or any combination thereof.

### Claim 18 (depends on 16)

The method of claim 16, wherein the anti-PD-L1 antibody comprises BMS-936559, MPDL3280A, MEDI4736, MSB0010718C, or any combination thereof.
